Clinical and experimental rheumatology · 2025
Effects of cetylated fatty acids on knee osteoarthritis: a systematic review and meta-analysis of real-world evidence.
СтатьяСистематический обзорМетаанализНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Tung Kuang-Mou, Pan Pin-Ho, Lin Ying-Tong, Nhu Nguyen Thanh, Wu Jia-Lin, Hu Chia-Chen, Chen Chiehfeng, Hou Wen-Hsuan
Аннотация
OBJECTIVES: Knee osteoarthritis (OA) continues to be a debilitating global health issue, with effective treatments that have minimal side effects still lacking in modern clinical practice. Cetylated fatty acids (CFAs), a group of esterified fatty acids administered either topically or orally to protect the synovial membrane and stabilise cell membranes, appears to be a promising therapeutic option.
METHODS: We conducted a comprehensive search in PubMed, Embase, Cochrane Library, CENTRAL, and Web of Science from the inception until November 2024 to examine the therapeutic effects of CFAs. We included randomised controlled trials (RCTs) with a CFA intervention group compared with a control group that received either a placebo or a non-CFA treatment, as well as pre-post experimental studies that investigate pre-treatment and post-treatment CFA interventions. Subgroup analyses for different forms of CFAs were also conducted.
RESULTS: A total of 5 RCTs and 2 pre-post experimental studies with 357 participants were included. Significant improvements were observed in pain levels (SMD= -0.37, 95% CI= -0.60 to -0.15, p=0.0009), knee ROM (SMD=7.80, 95% CI=4.15 to 11.45, p<0.0001), and physical function (SMD= -0.32, 95% CI= -0.51 to -0.13, p=0.0007) after CFA intervention. No significant difference was observed in the degree of knee stiffness. As for the subgroup analysis, the significant improvements in pain, ROM, and physical function only observed when using oral CFA capsules instead of CFA cream.
CONCLUSIONS: Overall, CFAs may improve pain levels, knee ROM, and physical function in patients with knee OA, particularly the oral form. Further research is required to determine the synergic effects as a supplementary regimen, longer term effects, and safety profiles of CFAs in patients with knee OA.
METHODS: We conducted a comprehensive search in PubMed, Embase, Cochrane Library, CENTRAL, and Web of Science from the inception until November 2024 to examine the therapeutic effects of CFAs. We included randomised controlled trials (RCTs) with a CFA intervention group compared with a control group that received either a placebo or a non-CFA treatment, as well as pre-post experimental studies that investigate pre-treatment and post-treatment CFA interventions. Subgroup analyses for different forms of CFAs were also conducted.
RESULTS: A total of 5 RCTs and 2 pre-post experimental studies with 357 participants were included. Significant improvements were observed in pain levels (SMD= -0.37, 95% CI= -0.60 to -0.15, p=0.0009), knee ROM (SMD=7.80, 95% CI=4.15 to 11.45, p<0.0001), and physical function (SMD= -0.32, 95% CI= -0.51 to -0.13, p=0.0007) after CFA intervention. No significant difference was observed in the degree of knee stiffness. As for the subgroup analysis, the significant improvements in pain, ROM, and physical function only observed when using oral CFA capsules instead of CFA cream.
CONCLUSIONS: Overall, CFAs may improve pain levels, knee ROM, and physical function in patients with knee OA, particularly the oral form. Further research is required to determine the synergic effects as a supplementary regimen, longer term effects, and safety profiles of CFAs in patients with knee OA.